Chapmans completes strategic investment in medical cannabis group, MJ Life Sciences

By Zoe Gross. Published at Sep 25, 2017, in Juniors

Diversified investment group, Chapmans Limited (ASX:CHP), has today announced the company’s successful completion of its strategic investment in MJ Life Sciences (MJLS).

MJLS is an Australian special-purpose company established with the aim of becoming a leading global medicinal cannabis holding and investment company.

It is also a direct investor in Caziwell Inc., owner of the established North American medicinal cannabis brand and business, Aunt Zelda’s, with convertible note rights of up to 49.99% in Caziwell Inc.

Prior to CHP’s investment, MJLS had been founded and owned by three of the leading names in the burgeoning Australian and global medicinal cannabis space: Harry Karelis, Jason Peterson and Dr Stewart Washer, founders and/or directors of Auscann Group Holdings Limited (ASX:AC8), Zelda Therapeutics Limited (ASX:ZLD), CannPal Animal Therapeutics Ltd, and specialist cannabis medical clinic operator, CliniCann Ltd.

Between them, these major players have expansive regulatory, technical, operational and transactional experience in the industry.

CHP’s opportunity to invest directly in MJLS is highly advantageous, as well as consistent with its strong conviction and capital growth investment philosophy, enabling direct exposure to its future investments in the rapidly growing global medicinal cannabis landscape.

This company is in early stages of development and remains a speculative investment option, so investors should seek professional financial advice if considering this stock for their portfolio.

The investment also represents a significant value accretive transaction for CHP, paving the way for a strategic long-term partnership with MJLS.

Under the terms and conditions of the investment:

  • Chapmans has invested AUD 631,313 (reflecting the AUD equivalent of USD 500,00 in exchange for a 50% equity holding in MJLS; and
  • Chapmans has the right to equal board representation to the existing MJLS shareholders and will control 50% of the board with the existing MJLS shareholders collectively controlling the remaining 50% of the board

The MJLS investment has been funded from the proceeds from the placement announced by the company last week and existing capital.

MJLS’s board of directors will be reviewing its investment strategy and focus, with a view to securing additional medicinal cannabis opportunities in the near term ahead of a potential ASX listing in 2018.

CHP executive chairman, Peter Dykes, said: “Chapmans shares common investment principals and goals with MJLS and is delighted to be working with such experienced medicinal cannabis industry experts seeking to capitalise on clear and compelling growth market opportunities.”

Similarly, Harry Karelis, executive chairman of Zelda Therapeutics and executive director of Auscann, said: “MJLS welcomes the opportunity to join forces with Chapmans with whom we have clear alignment in investment approach and objectives. We are delighted to have completed this initial investment as scheduled and now look forward to immediately progressing to secure further compelling and unique investment opportunities in the burgeoning medicinal cannabis industry.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.